Bioventus IncNASDAQ:BVS
- LAST PRICE11.4900
- TODAY'S CHANGE (%)-0.2200 (-1.8787%)
- Bid / Lots11.4800/ 4
- Ask / Lots11.5000/ 1
- Open / Previous Close11.5200 / 11.7100
- Day Range
- 52 Week Range
- Volume168,367
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BVS |
|---|---|---|
| 09:32 ET | 21515 | 11.53 |
| 09:33 ET | 100 | 11.5409 |
| 09:35 ET | 123 | 11.59 |
| 09:39 ET | 5267 | 11.595 |
| 09:42 ET | 9028 | 11.7 |
| 09:44 ET | 336 | 11.63 |
| 09:46 ET | 300 | 11.735 |
| 09:48 ET | 200 | 11.82 |
| 09:50 ET | 200 | 11.82 |
| 09:51 ET | 300 | 11.83 |
| 09:53 ET | 1232 | 11.8083 |
| 09:55 ET | 400 | 11.81 |
| 09:57 ET | 600 | 11.745 |
| 10:00 ET | 100 | 11.745 |
| 10:02 ET | 200 | 11.71 |
| 10:08 ET | 1782 | 11.62 |
| 10:09 ET | 126 | 11.65 |
| 10:11 ET | 325 | 11.6 |
| 10:13 ET | 300 | 11.51 |
| 10:15 ET | 1050 | 11.59 |
| 10:18 ET | 200 | 11.62 |
| 10:24 ET | 200 | 11.62 |
| 10:26 ET | 1310 | 11.615 |
| 10:31 ET | 600 | 11.615 |
| 10:33 ET | 1866 | 11.53 |
| 10:36 ET | 467 | 11.51 |
| 10:38 ET | 300 | 11.5285 |
| 10:40 ET | 100 | 11.53 |
| 10:42 ET | 2596 | 11.53 |
| 10:44 ET | 1400 | 11.57 |
| 10:45 ET | 1050 | 11.555 |
| 10:47 ET | 200 | 11.59 |
| 10:49 ET | 100 | 11.61 |
| 10:51 ET | 830 | 11.61 |
| 10:54 ET | 748 | 11.6633 |
| 10:56 ET | 1055 | 11.64 |
| 10:58 ET | 100 | 11.62 |
| 11:00 ET | 400 | 11.6046 |
| 11:02 ET | 400 | 11.64 |
| 11:03 ET | 400 | 11.64 |
| 11:09 ET | 822 | 11.62 |
| 11:12 ET | 100 | 11.6147 |
| 11:14 ET | 100 | 11.625 |
| 11:16 ET | 100 | 11.61 |
| 11:18 ET | 257 | 11.58 |
| 11:20 ET | 100 | 11.58 |
| 11:21 ET | 2725 | 11.53 |
| 11:23 ET | 1100 | 11.5 |
| 11:27 ET | 874 | 11.49 |
| 11:32 ET | 200 | 11.485 |
| 11:34 ET | 600 | 11.5 |
| 11:36 ET | 200 | 11.5 |
| 11:38 ET | 539 | 11.48 |
| 11:39 ET | 200 | 11.475 |
| 11:43 ET | 1681 | 11.469 |
| 11:48 ET | 274 | 11.46 |
| 11:50 ET | 459 | 11.485 |
| 11:52 ET | 100 | 11.48 |
| 11:54 ET | 400 | 11.515 |
| 11:56 ET | 467 | 11.49 |
| 11:59 ET | 400 | 11.51 |
| 12:01 ET | 200 | 11.515 |
| 12:03 ET | 100 | 11.51 |
| 12:06 ET | 1103 | 11.51 |
| 12:08 ET | 100 | 11.52 |
| 12:10 ET | 100 | 11.52 |
| 12:12 ET | 700 | 11.5 |
| 12:14 ET | 760 | 11.48 |
| 12:15 ET | 1420 | 11.45 |
| 12:21 ET | 957 | 11.42 |
| 12:24 ET | 100 | 11.405 |
| 12:28 ET | 300 | 11.42 |
| 12:32 ET | 1698 | 11.41 |
| 12:33 ET | 2319 | 11.41 |
| 12:35 ET | 2200 | 11.4004 |
| 12:42 ET | 100 | 11.43 |
| 12:44 ET | 200 | 11.42 |
| 12:46 ET | 853 | 11.42 |
| 12:48 ET | 800 | 11.445 |
| 12:50 ET | 200 | 11.45 |
| 12:55 ET | 235 | 11.45 |
| 12:57 ET | 1300 | 11.4522 |
| 01:00 ET | 100 | 11.47 |
| 01:02 ET | 485 | 11.49 |
| 01:04 ET | 227 | 11.49 |
| 01:06 ET | 211 | 11.5 |
| 01:08 ET | 3244 | 11.495 |
| 01:09 ET | 200 | 11.515 |
| 01:11 ET | 409 | 11.5 |
| 01:15 ET | 160 | 11.464 |
| 01:18 ET | 419 | 11.47 |
| 01:22 ET | 561 | 11.45 |
| 01:24 ET | 600 | 11.46 |
| 01:26 ET | 100 | 11.47 |
| 01:31 ET | 100 | 11.4781 |
| 01:33 ET | 200 | 11.48 |
| 01:36 ET | 655 | 11.5 |
| 01:38 ET | 129 | 11.5 |
| 01:40 ET | 1200 | 11.52 |
| 01:42 ET | 793 | 11.510622 |
| 01:44 ET | 148 | 11.51 |
| 01:45 ET | 413 | 11.5 |
| 01:47 ET | 300 | 11.51 |
| 01:51 ET | 1000 | 11.5 |
| 01:54 ET | 200 | 11.5 |
| 01:56 ET | 5961 | 11.4413 |
| 02:00 ET | 100 | 11.49 |
| 02:02 ET | 324 | 11.49 |
| 02:03 ET | 359 | 11.49 |
Nov 6, 2024
DJ Bioventus Is Maintained at Buy by Canaccord Genuity, from 12:58PM ET on Wednesday Nov 06, 2024 by Dow Jones
12:58PM ET on Wednesday Nov 06, 2024 by Dow Jones
Nov 5, 2024
DJ Bioventus Down Nearly 19%, on Pace for Largest Percent Decrease Since August 2023 -- Data Talk, from 11:07AM ET on Tuesday Nov 05, 2024 by Dow Jones
11:07AM ET on Tuesday Nov 05, 2024 by Dow JonesBioventus Reports Third Quarter Financial Results, from 7:30AM ET on Tuesday Nov 05, 2024 by Dow Jones
7:30AM ET on Tuesday Nov 05, 2024 by Dow JonesPress Release: Bioventus Reports Third Quarter Financial Results, from 7:30AM ET on Tuesday Nov 05, 2024 by Dow Jones
7:30AM ET on Tuesday Nov 05, 2024 by Dow Jones
Oct 29, 2024
Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024, from 7:30AM ET on Tuesday Oct 29, 2024 by Dow Jones
7:30AM ET on Tuesday Oct 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Bioventus Inc | 950.3M | -18.6x | --- |
Figs Inc | 800.4M | 83.9x | --- |
Avanos Medical Inc | 854.8M | 41.6x | --- |
Artivion Inc | 1.2B | -1,217.1x | --- |
Paragon 28 Inc | 838.4M | -13.1x | --- |
Castle Biosciences Inc | 834.9M | 148.5x | --- |
Company Information
Bioventus Inc. is a medical device company. The Company is focused on developing and commercializing clinically differentiated and minimally invasive treatments that engage and enhance the body’s natural healing process. Its portfolio of products is grouped into three areas. Its Pain Treatments include non-surgical pain injection therapies as well as peripheral nerve stimulation (PNS) products to help the patient get back to their normal activities. Its Surgical Solutions include bone graft substitutes (BGS) that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries, as well as a portfolio of ultrasonic products used for precise bone cutting and sculpting, soft tissue management and tissue debridement in various surgeries. Its Restorative Therapies comprise a bone stimulation system, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis or other central nervous system disorders.
Contact Information
- Headquarters
- 4721 EMPEROR BOULEVARD, SUITE 100DURHAM, NC, United States 27703
- Phone
- 919-474-6700
- Fax
- 302-655-5049
Executives
- Non-Executive Independent Chairman of the Board
- William Hawkins
- President, Chief Executive Officer, Director
- Robert Claypoole
- Chief Financial Officer, Senior Vice President
- Mark Singleton
- Senior Vice President, Chief Compliance Officer
- Katrina Church
- Senior Vice President, General Counsel
- Anthony D'adamio
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $950.3M |
|---|---|
Revenue (TTM) | $555.1M |
Shares Outstanding | 81.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.80 |
EPS | $-0.62 |
Book Value | $2.20 |
P/E Ratio | -18.6x |
Price/Sales (TTM) | 1.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3.39% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
